

1 Dalmore Drive,
Scoresby,
Victoria 3179
AUSTRALIA
T: +61 (0)3 9763-1287
F: +61 (0)3 9763-2817
www.generabiosystems.com

Thursday 11 July 2019

**ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX: GBI)
APPOINTMENT OF EXECUTIVE DIRECTOR**

Genera Biosystems Limited (ASX:GBI) ('Genera' or 'the Company') is pleased to announce the appointment of Dr Damian Pethica as a Director of the Company and Executive Chairman.

Dr Pethica joined the Genera Leadership team in September 2018 assuming the role of Chief Medical Officer and is very familiar with Genera's core AmpaSand technology having researched the business in-depth in the mid-2000s prior to Genera being listed on the ASX.

Dr Pethica will be lead director of the Genera Board and shall strongly complement CEO Richard Hannebery and Dr Karl Poetter who has recently moved into a Non-Executive Director role. In addition to his role as Chairman Damian retains specific day-to-day executive responsibility for the design and implementation of the various clinical studies the Company is currently planning for its PapType HPV test as well as Chief Medical Officer and advisor for the launch and roll-out of Genera's new Companion Diagnostic business line.

A brief bio of Dr Pethica is provided below.

Dr Damian Pethica MA(Oxon), MBBS, FFPM – Executive Chairman & Chief Medical Officer

Damian initially worked for six years with the Pharmaceutical Division of Ciba-Geigy in Basel, Switzerland. In Basel he held roles as Medical Affairs Group Head of Oncology as well as Medical Adviser – Cardiovascular. After his time in Basel, Damian was promoted to the role of Medical Director of Ciba-Geigy/Novartis New Zealand, with responsibilities including registration, clinical development, pharmacoepidemiology and medical support for reimbursement negotiations.

He left Novartis to join Robert Flemings and then JP Morgan Chase, based in London as Vice President and Head of Biotechnology Equity Research Europe. After JP Morgan Chase Damian returned to New Zealand to live and has since undertaken a variety of specialist advisory and consulting roles in both New Zealand and Australia.

He was a member of the NZ Medicines Assessment Advisory Committee from 2002-2015, which has a role similar to the US FDA Advisory Committees for pharmaceuticals, and remains a current member of the NZ Standing Committee on Therapeutic Trials, which undertakes scientific reviews of proposed clinical trials of medicines in parallel with Ethics review. Many cancer clinical trials include exploratory genomics, with the goal of developing a Companion Diagnostic (CDx) to optimise efficacy.

Damian has consulted in the healthcare insurance sector, drafting guidelines and implementing decision making processes for the reimbursement of new medical technologies. Damian was also an Honorary Senior Lecturer, Epidemiology and Biostatistics, Auckland University, and is performing a tissue-based study reassessing the potential role of HPV in prostate cancer.

Damian studied mathematics at Oxford University, with BA First Class Honours, and then medicine at University College Hospital, London with MBBS followed by 7 years of clinical practice experience including anaesthetics and general practice. He is a Fellow of the Faculty of Pharmaceutical Physicians, Royal College of Physicians, London.

Damian has sound prior experience in lead director roles with small ASX listed companies undertaking restructures and recapitalisations while maintaining strong governance.

Dr Pethica's remuneration shall be \$125,000 per annum for his role as both Chairman and Chief Medical Officer and he shall be entitled to participate in the Company's Employee Share Option Plan (ESOP).

For further information please contact:

Mr Richard Hannebery
Chief Executive Officer
Genera Biosystems Limited
Telephone: +61 (0)3 9763 1287
www.generabiosystems.com.au